|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, December 11, 2009 ) DALLAS, Texas - BeaconEquity.com announces an investment report featuring biopharmaceutical company Cell Therapeutics Inc. (Nasdaq: CTIC).
It is available at: http://www.beaconequity.com/i/CTIC
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Cell Therapeutics Inc. is a biopharmaceutical company engaged in the development and commercialization of oncology drug therapies for the treatment of cancer. Its portfolio of trial therapies include Phase III candidate drug therapy, Pixantrone, for the treatment of non-Hodgkin's lymphoma; Phase II drug, Brostallicin, for the treatment of sarcoma; and OPAXIO for the treatment of non-small cell lung, ovarian and other forms of cancer. The Company partnered with Novartis International Pharmaceuticals Ltd. and PG-TXL Co. L.P. for various drug development.
In the report, the analyst notes:
“If approved by the U.S. Food and Drug Administration (FDA), the market for Cell Therapeutics' Phase III drug candidate, Pixantrone, could reach more than $1 billion at its market saturation. Data show that nine-out-of-ten drugs completing Phase III clinical trials eventually become commercial products.
Pharmaceutical companies with revenue of more than $1 billion include Cephalon Inc. (Nasdaq: CEPH), which trades at a market capitalization of $4.24 billion, and King Pharmaceuticals (Nasdaq: KG), which trades at a market capitalization of $2.81 billion. As of December 8, Cell Therapeutics trades at a market capitalization of $718 million.”
To read the entire report visit: http://www.beaconequity.com/i/CTIC
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Beacon Equity
Jeff Bishop
(469)-252-3505
press@beaconequity.com 
Source: EmailWire.com
|
|
|
|
